ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

STN1013800

A development code. Also written as “STN1013800 ophthalmic solution”.

Its studies are mostly in Blepharoptosis, led by Santen Pharmaceutical.

Furthest: phase 3, since Nov 8, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Santen Pharmaceutical21 open or runningphase 3since Nov 8, 2024Nov 8, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 8, 2024First study: phase 3 study in BlepharoptosisFirst studyNCT06683651 · 180 planned · China
  2. Mar 11, 2025Early phase 1 study in BlepharoptosisNCT06911216 · 8 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06911216Blepharoptosis · ChinaEarly 1CompletedApr 7, 20258
NCT06683651Blepharoptosis · China3RecruitingJun 2026180

How it is read

Names in the registry

  • “STN1013800 ophthalmic solution”, 2 entries

Codes read as this program: STN1013800.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.